Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

5075 Pages (Click to Jump) V  « < 839 840 841 842 843 844 845 > »    
 
  
Reply to this topic

CUV, CLINUVEL PHARMACEUTICALS LIMITED
marmas
post Posted: Nov 29 2018, 12:50 PM
  Quote Post


Posts: 51
Thanks: 29


In Reply To: LRR's post @ Nov 29 2018, 12:09 PM

My fingers have been crossed for so many christmas' past i think they are in a permanent bow!




--------------------
Hopefully nervous

Said 'Thanks' for this post: Kalaz  royco  johnnytech  xlnja  
 
LRR
post Posted: Nov 29 2018, 12:09 PM
  Quote Post


Posts: 220
Thanks: 114


very quiet here lately - anyone think that FDA news/decision will be forthcoming this year? :/ fingers crossed overall markets stay strong in mean time...


Said 'Thanks' for this post: royco  
 
seeva222
post Posted: Nov 28 2018, 09:46 AM
  Quote Post


Posts: 1,623
Thanks: 1857


In Reply To: sharelooker's post @ Nov 28 2018, 06:45 AM

France and England could go online at the same time

 
Johnny H
post Posted: Nov 28 2018, 08:52 AM
  Quote Post


Posts: 988
Thanks: 2084


In Reply To: polyphemus's post @ Nov 28 2018, 08:38 AM

Interesting to see Instinet in there. They're agency only; no retail investors.



--------------------
"In today’s world some shareholders enjoy complaining to Board and management but then they do not sell their stock, they hold on and sometimes buy even more."
 
polyphemus
post Posted: Nov 28 2018, 08:38 AM
  Quote Post


Posts: 548
Thanks: 913


Trading this month has been sideways - very similar routine each day - open high or low then watch the algo trading kick in and drive the price away from open. From observations there has been no real hard buying or selling. Its is hard to get any price formation or clue to value with $1 swings between high and low each day. Yesterday was slightly different - algo trading waited until 11:10am to start. usually see the activity a few minutes after open 10:05am

Quite annoying with an average trade value of the larger players of $500 per transaction or basically 30 units per transaction. Macquarie and Goldmans are at 12 shares per transaction.

The up shot is if you are buying don't chase let them come to you. If you are selling looking for afternoon rebounds.
Attached thumbnail(s)
Attached Image


 



Said 'Thanks' for this post: Farleap11  Johnny H  johnnytech  
 
polyphemus
post Posted: Nov 28 2018, 08:26 AM
  Quote Post


Posts: 548
Thanks: 913


While I wait for the ethical approval hopefully this month....it feels a lot like Tesla.

From the Nov Investor update
QUOTE
final protocol agreement with an academic centre[/b] which will conduct the pilot study in the third elected indication. CLINUVEL will announce this indication when all legal and administrative agreements have been completed. ]


A more detailed explanation of all that research that has been going on indicates supply chain improvements for the future:
QUOTE
We have surprisingly found that compounds of the present invention provide beneficial results in in-vitro and/or in-vivo tests for instance relating to MC1R binding affinity, potency, and/or efficacy or showing increased stability, and are in particular useful for increasing MC1R expression as a medicinal target. Further, we have found that compounds of the invention can safely and efficiently be synthesized, particularly at high yield.


3rd indications lead into the 4th and 5th ... from the patents there is a long expression of possibilities. But they need to get into the 1st round of trials
QUOTE
Preferably, compounds of the invention are used for treatment of diseases wherein the compounds -through association- beneficially increase MC1R expression, as a drug target for the diseases. Examples of such diseases are pigmentation disorders, photodermatoses, prevention of skin cancer, and/or DNA repair in skin cells (after/due to UV exposure). It will most certainly be understood by the skilled person that the disclosure of this specification includes the use of each specific compound of the present invention for each specific of the indications mentioned.

In one aspect, compounds of the invention are used for treatment of pigmentation (or skin pigmentation) disorders. Such disorder can either be hyperpigmentation but in this case particularly hypopigmentation disorders are important. We have found that compounds of the invention can induce melanogenesis and are useful for inducing therapeutic melanogenesis.
In an aspect, the invention relates to inducing melanogenesis in the skin as a treatment for pigmentation disorders with a compound according to the invention. The term “‘melanogenesis” as used herein is defined as the ability of a subject to produce melanin by melanin-producing cells called melanocytes, for therapeutic purposes. Examples of producing therapeutic melanogenesis are protecting the skin from UV irradiation damage, for instance preventing the skin from developing wrinkles, sun burns and/or cancer.

An important preferred example of a hypopigmentation disorder is vitiligo. Vitiligo is a chronic skin condition that is characterized by loss of pigment, including melanin, resulting in irregular pale, de-pigmented skin that has a different color and aspect than and contrast with the surrounding non-affected, pigmented, darker colored skin tissue. In an aspect, the present invention is directed to treatment of vitiligo, in particular in combination with UV light treatment. Compounds of the invention are preferred for use in the treatment of vitiligo, particularly for repigmentation of vitiliginous lesions and therefore reducing the contrast between the vitiliginous and the surrounding skin tissue.

Photodermatoses are skin diseases that are associated with photosensitivity of the skin to UV irradiation and may be classified into 5 general categories: idiopathic photodermatoses (including polymorphic light eruption (PLE), actinic prurigo, hydroa vacciniforme, chronic actinic dermatitis, and solar urticarial-SU); photodermatoses that are secondary to exogenous agents (including phototoxic and photoallergic reactions); photodermatoses secondary to endogenous agents (mainly the porphyrias including Erythropoietic PhotoPorphyria-EPP); photoexacerbated dermatoses (including autoimmune disease, infectious conditions, and nutritional deficiencies); and genodermatoses.

In an aspect, the present invention is directed to treatment of photodermatoses. Compounds of the present invention are preferred for use in treatment of photodermatoses, particularly for EPP, PLE, and SU, most particularly for EPP.

Skin cancer includes melanoma and non-melanoma cancer. Generally, higher skin melanin levels are considered a measure for prevention of skin cancer. In an aspect, the present invention is directed using the compounds of the invention for prevention of cancer. Compounds of the invention are preferred for use in the prevention of cancer, particularly skin cancer including melanoma and particularly non-melanoma. While the general public will benefit from skin cancer prevention through the invention, certain patient groups will in particular benefit from the use of compounds of the invention, including immunocompromised patients (particularly HIV-AIDS patients, allogeneic transplant patients, i.e. the recipient receives the transplant from another subject, and/or patients on immunosuppressant medication), human subjects having one or more MC1R variant alleles associated with loss of or diminished receptor function (preferably selected from Val60LEU (V60L), Asp84GIu (D84E), VaI92Met (V92M), Arg142His (R142H), Arg151Cys (R151C), Arg160Trp (R160W) and Asp294His (D294H)).
It is understood that UV irradiation can cause damage to DNA, particularly the DNA of dermal (skin) cells. In an aspect, the present invention is direct to DNA repair. Accordingly, the present invention is directed to compounds of the invention for use in DNA repair, preferably in the skin, particularly subsequent to UV irradiation of the skin.



Said 'Thanks' for this post: 9 lives  
 

Featured Stock Stories





FarmaZutical
post Posted: Nov 28 2018, 08:00 AM
  Quote Post


Posts: 612
Thanks: 2555


In Reply To: sharelooker's post @ Nov 28 2018, 06:45 AM

I’m surprised it’s not March 2020.

 
sharelooker
post Posted: Nov 28 2018, 06:45 AM
  Quote Post


Posts: 639
Thanks: 2610


Just updated!

https://www.nice.org.uk/guidance/indevelopment/gid-hst10009

Committee meeting 3: 14 March 2019


Said 'Thanks' for this post: CUV88  KRD  Frogster  Justinian  FarmaZutical  Farleap11  odi01  Texas T  investek  willo76  
 
sharelooker
post Posted: Nov 28 2018, 05:54 AM
  Quote Post


Posts: 639
Thanks: 2610


QUOTE
Afamelanotide has a promising future as a treatment for a variety of skin diseases including EPP, solar urticaria, PMLE, acne vulgaris, vitiligo and Hailey-Hailey disease. In consideration of the limited data available on afamelanotide use in children, elderly patients, pregnant or lactating women, and those with hepatic or renal impairment, more studies are needed to evaluate safety and efficacy in these populations.5 The anti-inflammatory, pigmenting and free radical scavenging effects produced by the stimulation of melanin production, coupled with a mild side effect profile, make afamelanotide an attractive and versatile compound that shows therapeutic potential in a variety of dermatologic conditions.


http://www.skintherapyletter.com/dermatology/afamelanotide/


Said 'Thanks' for this post: Farleap11  seeva222  Texas T  
 
CUV88
post Posted: Nov 28 2018, 05:14 AM
  Quote Post


Posts: 231
Thanks: 588


Yaaawwwnnn.... FDA???



--------------------
CLINUVEL's SCENESSE Potential: 1.)EPP 2.)Vitiligo 3.)SUN Protection and skin cancer prevention

Said 'Thanks' for this post: sharelooker  oystercatcher  
 
 


5075 Pages (Click to Jump) V  « < 839 840 841 842 843 844 845 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING